[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aplastic-anaemia-aa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aplastic-anaemia-aa":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100635424",false,"NCT07552506","Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin","Inclusion Criteria:\n\n(1) Patients clinically diagnosed with SAA and scheduled for allogeneic haematopoietic stem cell transplantation (allo-HSCT); (2) Female patients aged 14 to 50 years, within reproductive age, with regular menstrual cycles prior to transplantation; (3) Patients or their legal representatives voluntarily participate and sign informed consent forms, demonstrating comprehension and willingness to comply with all study procedures and requirements; (4) Patients with an estimated survival period exceeding one year to ensure sufficient time for monitoring menstrual recovery.\n\nExclusion Criteria:\n\n(1) Patients with severe dysfunction of vital organs such as the heart, liver, or kidneys, which may compromise study outcomes or increase patient risk; (2) Patients with a history of allergy to goserelin or related medications; (3) Patients who have previously undergone menopause due to physiological or pathological factors; (4) Patients with a history of gynaecological conditions (e.g., polycystic ovary syndrome, endometriosis) that may interfere with the assessment of menstrual recovery; (5) Patients currently participating in other clinical studies that may influence menstrual recovery; (6) Patients who refuse to participate in this clinical study.","FEMALE","14 Years","50 Years",{"count":18,"type":19},132,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study is a prospective, randomized, controlled, multicenter clinical trial. It plans to enroll 132 female SAA patients aged 14-50 years from multiple medical centers nationwide who are scheduled to undergo allo-HSCT. Patients will be divided into two groups based on whether they receive busulfan conditioning: the busulfan-conditioned group (Bu group) and the non-busulfan-conditioned group (non-Bu group). Within each group, patients will be randomly assigned 1:1 to either the experimental group (Goserelin prophylaxis group) or the control group using a random number table. The experimental group will receive a single 3.6 mg subcutaneous injection of Goserelin 1-3 days prior to conditioning, in addition to the standard transplantation regimen. The control group will not receive Goserelin prophylaxis. The primary endpoint was menstrual recovery rate at 6 months post-transplant (defined as ≥3 naturally occurring menstrual cycles without intervention by menstrual-regulating drugs). Secondary endpoints included: incidence of premature ovarian insufficiency (POI); ovarian reserve function markers: anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) levels; Additional reproductive parameters: ovarian and uterine volume, endometrial thickness; time to neutrophil\u002Fplatelet engraftment; incidence of acute\u002Fchronic graft-versus-host disease (aGVHD\u002FcGVHD), EBV\u002FCMV infection rates; transplant-related mortality; and adverse event (AE) occurrence. This study aims to evaluate the efficacy and safety of goserelin in preserving ovarian function following allo-HSCT.",[25,26,27],"Aplastic Anaemia (AA)","Allogeneic Haematopoietic Stem Cell Transplantation","Ovarian Insufficiency",[29,30,31],"Aplastic anaemia","Allogeneic haematopoietic stem cell transplantation","Ovarian insufficiency","NOT_YET_RECRUITING","2026-04-20",{"date":35,"type":36},"2026-04-27","ACTUAL",{"date":38,"type":19},"2026-05-01",{"date":40,"type":19},"2027-10-01",{"name":42,"class":43},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",5,{"id":46,"slug":4,"hasResults":10,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":10,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100603081","NCT07131878","Assesment of Treatment Outcomes of Aquired Aplastic Anemia in Children : A Retrospective and Prospective Cohort","TTT","Inclusion Criteria:\n\n* Children aged 1-18 years diagnosed with acquired aplastic anemia, as confirmed by bone marrow examination and fulfilling diagnostic criteria (e.g., bone marrow cellularity \\\u003C25% and at least two of the following: absolute neutrophil count \\\u003C500\u002FμL, platelet count \\\u003C20,000\u002FμL, absolute reticulocyte count \\\u003C60,000\u002FμL)123.\n* The bone marrow biopsy should be compitable with diagnosis\n* Diagnosed and\u002For treated at Assiut University Children's Hospital between Agust 2023 and Augst 2026.\n* Patients with complete medical records, including diagnostic, laboratory, and treatment data\n\nExclusion Criteria:\n\n* Patients with inherited bone marrow failure syndromes (e.g., Fanconi anemia, dyskeratosis congenita) as confirmed by genetic testing or family history21.\n* Patients with incomplete or missing essential data in their medical records.\n* Patients diagnosed outside the specified study period or managed primarily at other institutions.\n* Patinets with neoplastic or granulomatous disease involving the bone marrow, systemic lupus erythematosus, AIDS, hypersplenism or other conditions associated with pancytopenia such as myelodysplastic syndrome,and paroxysmal nocturnal hemoglobinuria.\n* Patients exposed to antineoplastic chemotherapy or radiotherapy were excluded","ALL","1 Year","18 Years",{"count":55,"type":19},35,"OBSERVATIONAL","The goal of this observational study is to to assess of treatment Outcomes of Aquired Aplastic Anemia in children",[25],"2025-08-13",{"date":61,"type":36},"2025-08-20",{"date":63,"type":19},"2025-09-15",{"date":65,"type":19},"2028-01-15",{"name":67,"class":43},"Assiut University",""]